0001628280-20-017743.txt : 20201223 0001628280-20-017743.hdr.sgml : 20201223 20201223182355 ACCESSION NUMBER: 0001628280-20-017743 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201222 FILED AS OF DATE: 20201223 DATE AS OF CHANGE: 20201223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FLANAGAN JOSEPH GERARD CENTRAL INDEX KEY: 0001413644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34746 FILM NUMBER: 201413895 MAIL ADDRESS: STREET 1: C/O NORTEL NETWORKS CORPORATION STREET 2: 195 THE WEST MALL CITY: TORONTO STATE: A6 ZIP: M9C 5K1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: R1 RCM INC. CENTRAL INDEX KEY: 0001472595 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT SERVICES [8741] IRS NUMBER: 020698101 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 401 NORTH MICHIGAN AVENUE STREET 2: SUITE 2700 CITY: CHICAGO STATE: IL ZIP: 60611 BUSINESS PHONE: 312-324-7820 MAIL ADDRESS: STREET 1: 401 NORTH MICHIGAN AVENUE STREET 2: SUITE 2700 CITY: CHICAGO STATE: IL ZIP: 60611 FORMER COMPANY: FORMER CONFORMED NAME: Accretive Health, Inc. DATE OF NAME CHANGE: 20090918 4 1 wf-form4_160876582170195.xml FORM 4 X0306 4 2020-12-22 0 0001472595 R1 RCM INC. RCM 0001413644 FLANAGAN JOSEPH GERARD C/O R1 RCM INC. 401 N. MICHIGAN AVENUE, SUITE 2700 CHICAGO IL 60611 1 1 0 0 President and CEO Common Stock 2020-12-22 4 M 0 860538 0 A 1925060 D Common Stock 2020-12-22 4 M 0 2581614 0 A 4506674 D Common Stock 2020-12-22 4 F 0 1524875 23.43 D 2981799 D Performance-Based Restricted Stock Units 2020-12-22 4 M 0 860538 0 D Common Stock 860538.0 0 D Performance-Based Restricted Stock Units 2020-12-22 4 M 0 2581614 0 D Common Stock 2581614.0 0 D Represents shares of common stock received upon settlement of performance-based restricted stock units ("PBRSUs"). Represents a contingent right to receive the Issuer's common stock. On February 16, 2018, the reporting person was granted PBRSUs that were previously reported on Table II of Form 4 filed on February 16, 2018. Pursuant to the award agreement, the PBRSUs were subject to both a time-based vesting condition and a performance-based vesting condition based upon an average per share price of the Issuer's common stock as defined in the award agreement, measured at December 22, 2020. At target, the PBRSUs covered 245,868 shares. Because the average price per share at the end of the performance period exceeded the maximum target of $9.00 per share, the reporting person earned the maximum number of shares, or 350% of the target award. The time-based vesting condition was fully satisfied on December 22, 2020. On December 20, 2017, the reporting person was granted PBRSUs that were previously reported on Table II of Form 4/A filed on January 18, 2018. Pursuant to the award agreement, the PBRSUs were subject to both a time-based vesting condition and a performance-based vesting condition based upon an average per share price of the Issuer's common stock as defined in the award agreement, measured at December 22, 2020. At target, the PBRSUs covered 737,604 shares. Because the average price per share at the end of the performance period exceeded the maximum target of $9.00 per share, the reporting person earned the maximum number of shares, or 350% of the target award. The time-based vesting condition was fully satisfied on December 22, 2020. /s/ E. Terry Platis, Attorney-in-Fact 2020-12-23